Clinical Scorecard: Hysterectomy Linked to Increased Risk of Sarcopenia in Women in the US and Animal Models

At a Glance

Key Highlights

• Hysterectomy is associated with an increased risk of sarcopenia (OR = 1.35).
• The risk is higher in women who have undergone both hysterectomy and oophorectomy (OR = 2.06).
• SAMP8 mouse model shows reduced grip strength and muscle fiber size post-hysterectomy.
• Molecular analyses indicate activation of the FOXO1–MuRF-1/Atrogin-1 pathway.
• Sarcopenia prevalence is particularly significant among postmenopausal women.

Guideline-Based Recommendations

Diagnosis

• Sarcopenia diagnosed using ALM/BMI < 0.512 criteria.

Management

• Further studies needed to clarify causality between hysterectomy and sarcopenia.

Monitoring & Follow-up

• Monitor muscle function and related health outcomes in women post-hysterectomy.

Risks

• Increased risk of cardiovascular disease, osteoporosis, and metabolic disorders post-hysterectomy.

Patient & Prescribing Data

Women undergoing hysterectomy, particularly postmenopausal.

Consideration of sarcopenia risk in surgical decision-making.

Clinical Best Practices

• Assess muscle mass and strength in women post-hysterectomy.
• Evaluate hormonal and metabolic factors influencing sarcopenia.

Related Resources & Content

• National Health and Nutrition Examination Survey (NHANES)
• Foundation for the National Institutes of Health (FNIH) criteria